Status:
COMPLETED
Clinical Study of Generic and Brand Bupropion in Depression
Lead Sponsor:
Washington University School of Medicine
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
Detailed Description
The protocol is a prospective, randomized, double-blinded, crossover study with Major Depressive Disorder (MDD) receiving bupropion HCl 300mg XL (branded or generic). Subjects will be studied in 4 ph...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Each subject must meet all of the following criteria:
- Adult outpatients age 18-75 years
- Currently on once daily bupropion HCl 300mg XL (brand or any generic), for a minimum of 4 months
- Major depressive disorder (MDD), in partial or full remission for at least 4 months, as confirmed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Spontaneous relapse of depression unrelated to medication changes is less likely - about 5% chance per year - after remission has been maintained for at least 4 months.2
- Ability to understand and willingness to comply with study procedures, and to provide written informed consent
- Exclusion Criteria
- Subjects will not be enrolled if any of the following criteria exist:
- Remission from depression not clearly attributed to bupropion treatment
- Current severe side effects attributable to bupropion
- Poor adherence to bupropion treatment per patient self- report and history of refill persistence
- History of active seizure disorder, or seizure treatment within past year
- History of significant hepatic or renal disease, based on physician assessment
- Currently taking drugs or natural products known to influence cytochrome P450B6 (CYP2B6) activity
- Currently taking drugs for hepatitis C or multiple sclerosis, due to their ability to cause depression
- Dementia or other significant cognitive impairment, per diagnosis or investigative team's assessment
- Lifetime diagnosis of schizophrenia, schizoaffective or schizophreniform dis-order, delusional disorder, or current psychotic symptoms diagnosed by SCID
- Abuse of or dependence on alcohol or other substances within the past 6 months as determined by SCID, and confirmed by study physician interview
- Current suicidal ideation
Exclusion
Key Trial Info
Start Date :
June 25 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 14 2016
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT02209597
Start Date
June 25 2014
End Date
August 14 2016
Last Update
April 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110